Parallel-Group,Double-Blind,Double-Dummy,Superiority Study of Etoricoxib90mg/ Cyclobenzaprine15mg From Eurofarma Versus Etoricoxib90mg (Arcoxia®) and Cyclobenzaprine15mg (XL - Mitrul®) for Muscle Spasm After Third Molar Extraction in Brazil

Etoricoxib and cyclobenzaprine hydrochloride are active pharmaceutical ingredients (APIs) already registered in the country as mono-drugs. These products are widely used for the proposed indications, and their safety and efficacy profiles are known in daily clinical practice. Once the absence of a pharmacokinetic interaction between etoricoxib and cyclobenzaprine hydrochloride has been confirmed in relative bioavailability studies, this phase 3 study will be conducted for demonstrating the superiority of the new FDC over etoricoxib 90 mg (Arcoxia®) and cyclobenzaprine hydrochloride 15 mg (XL - Mitrul®) in the treatment of moderate to serious pain associated with muscle spasm. The purpose is to provide a new, effective, and safe therapeutic option to address these cases. Etoricoxib and cyclobenzaprine hydrochloride are active pharmaceutical ingredients (APIs) already registered in the country as mono-drugs. These products are widely used for the proposed indications, and their safety and efficacy profiles are known in daily clinical practice. Once the absence of a pharmacokinetic interaction between etoricoxib and cyclobenzaprine hydrochloride has been confirmed in relative bioavailability studies, this phase 3 study will be conducted for demonstrating the superiority of the new FDC over etoricoxib 90 mg (Arcoxia®) and cyclobenzaprine hydrochloride 15 mg (XL - Mitrul®) in the treatment of moderate to serious pain associated with muscle spasm. The purpose is to provide a new, effective, and safe therapeutic option to address these cases.

Start Date30 May 2026

Sponsor / Collaborator

Eurofarma Laboratórios SA

NCT05118672

/ RecruitingPhase 3

A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and Cold

A Phase 3, multicenter, Randomized, Double-blind, comparative clinical trial to evaluate the association of paracetamol 500mg + Fexofenadine 60mg + Phenylephrine 20mg in the flu and common cold treatment.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Start Date26 Mar 2025

Sponsor / Collaborator

Eurofarma Laboratórios SA

NCT03792295

/ WithdrawnPhase 2IIT

The Effect of Multimodal Pain Therapy After Hernia Repair

Investigating the effect of multimodal pain treatment after hernia repair

Start Date01 Jul 2021

Sponsor / Collaborator-

100 Clinical Results associated with COXs x α-adrenergic receptor x Histamine receptor

100 Translational Medicine associated with COXs x α-adrenergic receptor x Histamine receptor

0 Patents (Medical) associated with COXs x α-adrenergic receptor x Histamine receptor

Literatures (Medical) associated with COXs x α-adrenergic receptor x Histamine receptor

01 Apr 2021·British Journal of DermatologyQ1 · MEDICINE

An additional drug repurposing study for hidradenitis suppurativa/acne inversa

Q1 · MEDICINE

Letter

Author: Readhead, B. ; Dudley, J.T. ; Zouboulis, C.C.

Current transcriptome and proteome studies have identified differentially regulated genes and proteins in hidradenitis suppurativa/acne inversa (HS), both in entire involved skin and in involved skin apocrine glands.In this report, we provide addnl. information obtained by further anal. of our data using mol. drug information available through chemogenomic studies.Raw microarray profiles from our own previous studies downloaded from Gene Expression Omnibus (GSE137141) and (GSE144801) were used in this study.The data for anal. originated from whole lesional skin (LS) and nonlesional skin (NLS) of 28 European patients [20 female, eight male; aged 35.0 (10.2) years] with active HS Hurley stage II-III and healthy skin (CS) of 12 matched controls [aged 37.1 (13.2) years].The comparison of LS vs. NLS revealed several new drug target genes, namely ABAT, ADH1C, ADIRF, ADRA1A, ANDR, CFD, CHRM1, CLEC3B, CP3A4, DACB, DRD1, DRD5, GABBR1, GBP6, GBRA6, GBRR1, GCR, GPD1, GRIA1, GRM4, HRH1, IF4H, KRT6B, LPA, MCR, MRCA, MRCB, OPRD, OPRM, PA24A, PBPC, PLAT, PLG, PRKAB1, PTGS1, PTGS2, RPL38, SLC6A4, TA2R, TBXA2R, THAS, TLR2 and UTS2, in addition to the ones detected as HS biomarkers in our previous study, namely DEFB4A/ DEFB4B, GJB2, KRT6A, KRT16, MMP1, MMP9, PI3, S100A7A, S100A8, S100A9, S100A12, SERPINB3, SERPINB4 and SPRR3.Therefore, repurposing drugs may become future targets of investigator-initiated studies supported from peer-reviewed public funding sources.

01 Dec 1996·General Pharmacology: The Vascular System

Local regulation of oviductal blood flow

Review

Author: Triguero, Domingo ; Garcia-Pascual, Angeles ; Labadia, Alicia ; Costa, Gonzalo

1. Blood flow to the oviduct is implicated in the genesis and maintenance of oviductal fluid, in this way contributing to the creation of an adequate medium for ovum/embryo physiology. Therefore, factors controlling the tone of the vessels supplying the oviduct would be expected to affect its luminal environment. In addition, cyclic changes in oviductal blood flow have been suggested to have mechanical functions in the transport of the ovum/embryo. 2. The vascular supply to the oviduct has a prominent adrenergic vasomotor control. A dense adrenergic innervation, together with the presence of a predominant population of alpha(1)-adrenoceptors, provides a contractile regulatory mechanism of oviductal blood flow. No evidence is available on the presence of beta-adrenoceptors. The scanty cholinergic innervation of mammalian oviduct is mainly confined to the vessels, where acetylcholine (ACh) has a vasodilatory effect by releasing endothelium-derived relaxing factors. 3. The presence of nerves containing neuropeptides has been shown in the oviduct. Specifically, a high density of neuropeptide Y- and vasointestinal peptide-containing nerve fibers has been found in relation to blood vessels, but their role in the neutral control of the oviduct blood flow remains to be established. To date, it is not known whether or not oviductal blood vessels receive perivascular nitrergic nerves. 4. Relaxing and contracting factors derived from endothelium also seem to have a modulatory role on oviductal vascular tone. Neurotransmitters or autacoids, such as ACh and histamine, acting on endothelial receptors, release nitric oxide (NO), which relaxes oviductal arteries through guanylyl cyclase activation and accumulation of cyclic GMP. In addition, the release of an endothelium-derived hyperpolarizing factor (EDHF), distinct from NO, by ACh has been shown in oviductal arteries. It acts through the opening of low-conductance Ca(2+)-activated K+ channels leading to hyperpolarization and relaxation. Furthermore, potent and long-lasting contractions induced by the endothelium-derived contractile factor, endothelin (ET), points to its role in the long-term regulation of oviductal vascular tone. 5. A particularly high density of 5-hydroxytryptamine (5-HT) and histamine, present in mast cells clustered in the vicinity of blood vessels, has been described in the oviduct. It is known that histamine elicits a relaxation of oviductal arteries that is partially endothelium-dependent and mediated by the activation of H1-receptors. The implication of histamine in both the increase in blood flow and edema around ovulation, as well as the existence of a functional antagonism between histamine and 5-HT in the regulation of oviductal blood flow, await further investigation. 6. Other factors, such as relaxing and contracting cyclooxygenase-derived products, may also participate in the modulation of blood flow to the oviduct. 7. An overall endocrine regulation of the oviductal vascular supply exists, acting by both direct effects on smooth muscle and modulation of neural and autocrine factors. This control enables cyclic changes in blood flow to the oviduct that are tightly coupled to the reproductive functions of the tube.

01 Jun 1993·The Journal of Pharmacology and Experimental Therapeutics

Endothelium- and beta-2 adrenoceptor-independent relaxation of rat aorta by tyramine and certain other phenylethylamines.

Article

Author: Chemtob, S ; Varma, D R

At concentrations higher than that required to produce maximal vasoconstriction, tyramine caused concentration-dependent relaxation of rat aortic strips contracted maximally by tyramine, norepinephrine, phenylephrine, 5-hydroxytryptamine, prostaglandin F2 alpha, endothelin, angiotensin II and potassium; isoproterenol did not relax potassium-contracted strips. The vasorelaxant effect of tyramine was not antagonized by propranolol, pindolol or nadolol, all of which markedly antagonized the effects of isoproterenol. The vasorelaxant activity of tyramine was endothelium-independent and not inhibited by hemoglobin, methylene blue or L-NG-nitro arginine; it did not exhibit tachyphylaxis and was neither inhibited by cocaine, guanethidine, reserpine and chemical sympathectomy nor by alpha adrenoceptor, dopamine receptor, 5-hydroxytryptamine receptor, histamine receptor and adenosine receptor antagonists. Inhibition of cyclooxygenase, lipoxygenase and monamine oxidase activities did not decrease the vasorelaxant activity of tyramine. The vasorelaxant effect of tyramine was not decreased by altering external calcium from 0.25 to 4 mM nor was it potentiated by nifedipine. Phenylethylamine was the minimum structural requirement for this propranolol-resistant vasorelaxant activity; beta-carbon and 3-ring hydroxylation abolished this activity, but N-methylation partly overcame the effect of beta-hydroxylation. The vasopressor effect of tyramine in anesthetized rat was reversed to vasodepressor effect by phenoxybenzamine plus propranolol. The propranolol-resistant vasorelaxant effect of tyramine was also confirmed on isolated human placenta arteries. At vasorelaxant concentrations, tyramine did not increase cyclic GMP and cyclic AMP but inhibited inositol-1,4,5-triphosphate. It is suggested that at high concentrations tyramine and related phenylethylamines cause endothelium- and beta-2 adrenoceptor independent vasorelaxation either via specific tyramine receptors or nonselectively.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

COXs x α-adrenergic receptor x Histamine receptor

Basic Info

Related

Analysis